Myriad Genetics Inc (NQ: MYGN )

30.10 USD +1.07 (+3.69%)

Official Closing Price Updated: 4:33 PM EST, Feb 24, 2021 Add to My Watchlist

Price and Volume

Volume	783,900
Open	28.41
Bid (Size)	25.00 (1)
Ask (Size)	32.00 (1)
Prev. Close	29.03
Today's Range	27.52 - 31.29
52wk Range	9.240 - 31.59
Shares Outstanding	69,906,818
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

February 23, 2021

Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives

February 18, 2021

New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal

Performance

YTD	+51.10%	+51.10%
1 Month	+13.37%	+13.37%
3 Month	+65.29%	+65.29%
6 Month	+112.72%	+112.72%
1 Year	+67.32%	+67.32%

More News

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

February 16, 2021

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

February 12, 2021

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

February 11, 2021

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

February 08, 2021

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

February 02, 2021

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

January 18, 2021

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

January 11, 2021

Recap: Myriad Genetics Q2 Earnings

February 23, 2021

Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations

January 05, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.